CERT:NSD-Certara Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 14.15

Change

0.00 (0.00)%

Market Cap

USD 1.60B

Volume

2.11M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara I

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-20 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

N/A

USD 28.76B
TEM Tempus AI, Inc. Class A Common..

N/A

USD 9.00B
HQY HealthEquity Inc

N/A

USD 7.52B
WAY Waystar Holding Corp. Common S..

N/A

USD 4.47B
BTSG BrightSpring Health Services, ..

N/A

USD 3.00B
PRVA Privia Health Group Inc

N/A

USD 2.92B
PINC Premier Inc

N/A

USD 1.93B
SDGR Schrodinger Inc

N/A

USD 1.79B
GDRX Goodrx Holdings Inc

N/A

USD 1.73B
OMCL Omnicell Inc

N/A

USD 1.53B

ETFs Containing CERT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.86% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.86% 93% A 94% A
Trailing 12 Months  
Capital Gain -11.17% 65% D 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.17% 65% D 44% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.60% 33% F 15% F
Dividend Return -17.60% 33% F 15% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.35% 95% A 77% C+
Risk Adjusted Return -90.98% 15% F 5% F
Market Capitalization 1.60B 79% B- 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.